Drug intelligence / Profile preview

NPB

Development stage: Preclinical
Lead developer: Sojo University
Modality: Small Molecules
Administration: Intravenous

Overview

NPB (nitrated form of phenylbutyrate) is a novel nitric oxide donor synthesized from chlorambucil. It is being developed as a potential chemotherapeutic agent for pancreatic cancer. NPB induces cell death in human pancreatic cancer cells primarily through necrosis, rather than apoptosis, and also causes S-phase cell cycle arrest. Its design leverages the high affinity of phenylbutyrate to human serum albumin (HSA) to achieve sustained blood retention and selective accumulation in tumor tissue via the enhanced permeation and retention (EPR) effect, allowing for gradual nitric oxide release.

Other names: nitrated form of phenylbutyrate4-(4-(bis(2-(nitrooxy)ethyl)amino)phenyl)butanoic acid

Targets

BAD (Bcl-2-associated agonist of cell death)B-cell lymphoma 2/BCL2-associated agonist of cell death protein–protein interface

Beyond the preview

Go deeper on NPB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPB.

Explore the full profile